#Inflammatory Bowel Disease Treatment Market Share
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
In February 2021, Tumblr had 518.6 million blog accounts.
Text
Inflammatory Bowel Disease Treatment Market Global Demand Analysis: Sales Consumption, Business Scenario, and Expert Reviews, Forecast by 2032
The Market Dynamics of the Inflammatory Bowel Disease Treatment
The global Inflammatory Bowel Disease Treatment market has emerged as a critical focal point for businesses, offering a wealth of opportunities and challenges. As industries navigate this complex landscape, understanding the underlying market dynamics becomes crucial for strategic decision-making and growth.
According to Straits Research, the global inflammatory bowel disease treatment market size was valued at USD 20.33 Billion in 2022. It is projected to reach from USD XX Billion in 2023 to USD 27.95 Billion by 2031, growing at a CAGR of 3.6% during the forecast period (2023–2031).
Historically, the Inflammatory Bowel Disease Treatment market has witnessed significant transformations, driven by technological innovations, regulatory changes, and evolving consumer preferences. These shifts have reshaped the market landscape, presenting businesses with new avenues for growth, innovation, and competitiveness.
Note: Our reports are currently under revision. To access the most recent primary and secondary data spanning 2023-2031, inclusive of Cost Module, Business Strategy, and Competitive Landscape insights, please click on ""request free sample report."" Expect the report in your inbox within 24 to 48 hours.
Get Access to a Free Copy of Our Latest Sample Report@https://straitsresearch.com/report/inflammatory-bowel-disease-treatment-market/request-sample
Companies and Manufacturers Covered:
Key market players play a pivotal role in shaping the market narrative. By profiling industry leaders, their strategic initiatives, and competitive positioning, the report offers insights into market dynamics, influencing factors, and growth opportunities. These insights are invaluable for businesses seeking to gain a competitive edge, drive innovation, and capitalize on emerging trends.
AbbVie Inc.
Takeda Pharmaceutical Company Limited
Pfizer Inc
Biogen
Novartis AG, Lilly
UCB S.A.
CELLTRION INC.
Merck & Co., Inc
Johnson & Johnson Services, Inc.
The quantitative analysis accompanying the report offers a decade-long perspective on the market's trajectory. By examining historical data, identifying trends, and forecasting future developments, stakeholders can gain a deeper understanding of market dynamics and make informed decisions.
Buy this Premium Research Report@https://straitsresearch.com/buy-now/inflammatory-bowel-disease-treatment-market
A recent comprehensive analysis provides a detailed overview of the Global Inflammatory Bowel Disease Treatment Market, highlighting key growth drivers, emerging trends, and market dynamics. This report serves as an invaluable resource for businesses, offering insights into the market landscape, competitive positioning, and growth prospects.
Global Regional Outlook:
North America: North America is currently the largest market for Inflammatory Bowel Disease Treatment, accounting for a significant share of the global market.
Asia-Pacific: While the North America leads in market size, Asia-Pacific is emerging as the fastest growing region in the Inflammatory Bowel Disease Treatment market.
Research Methodology
The research methodology employed in curating this report is rigorous and comprehensive. By leveraging both primary and secondary data sources, the report ensures accuracy, reliability, and depth. Through interviews with industry experts, analysis of Inflammatory Bowel Disease Treatment market trends, and examination of key growth drivers, the report offers a holistic view of the market landscape.
Market Segmentation:
By Type
Crohn’s Disease
Ulcerative Colitis
By Drug Class
Aminosalicylates
Corticosteroids
TNF inhibitors
IL inhibitors
Anti-integrin
JAK inhibitors
Others
By Route of Administration
Injectable
Oral
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Ask Here For More Customization Study@https://straitsresearch.com/report/inflammatory-bowel-disease-treatment-market/toc
Report Features:
Actionable market intelligence for strategic decision-making
Comprehensive forecasts spanning 2018to 2031
In-depth growth trend assessments
Segment-specific and regional revenue projections
Competitive analysis and market share insights
Innovative product listings for competitive advantage
Insights into the market implications of COVID-19
Report availability in various formats: PDF, XLS, PPT, and digital dashboards
In conclusion, the global Inflammatory Bowel Disease Treatment market presents a dynamic and evolving landscape for businesses. By understanding market dynamics, leveraging strategic insights, and adopting a proactive approach, businesses can navigate this complex landscape successfully, drive growth, and achieve sustainable success.
Report Customization:
Our report is adaptable to your specific needs. For tailored insights, please reach out to our sales team at [email protected]. Additionally, you can contact our representatives directly at +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.) to discuss your research criteria.
#Inflammatory Bowel Disease Treatment Market#Inflammatory Bowel Disease Treatment Market Share#Inflammatory Bowel Disease Treatment Industry#Inflammatory Bowel Disease Treatment Market Size#Inflammatory Bowel Disease Treatment Market Research#What is Inflammatory Bowel Disease Treatment?#Inflammatory Bowel Disease Treatment Market Drivers#North America Inflammatory Bowel Disease Treatment Market#Europe Inflammatory Bowel Disease Treatment Market#Asia Pacific Inflammatory Bowel Disease Treatment Market#LAMEA Inflammatory Bowel Disease Treatment Market#Global Inflammatory Bowel Disease Treatment Market
0 notes
Text
Inflammatory Bowel Disease Market expected to rise | Companies- Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market
The Inflammatory Bowel Disease market growth is driven by factors like increase in the prevalence of Inflammatory Bowel Disease, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Inflammatory Bowel Disease market report also offers comprehensive insights into the Inflammatory Bowel Disease market size, share, Inflammatory Bowel Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Inflammatory Bowel Disease market size growth forward.
Some of the key highlights from the Inflammatory Bowel Disease Market Insights Report:
Several key pharmaceutical companies, including Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, and others, are developing novel products to improve the Inflammatory Bowel Disease treatment outlook.
The total Inflammatory Bowel Disease market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Inflammatory Bowel Disease market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Inflammatory Bowel Disease Market Landscape
Inflammatory Bowel Disease Overview
Inflammatory bowel disease (IBD) is a term that describes disorders involving long-standing (chronic) inflammation of tissues in your digestive tract. Types of IBD include: Ulcerative colitis. This condition involves inflammation and sores (ulcers) along the lining of your large intestine (colon) and rectum.
Inflammatory bowel disease (IBD) is a term that describes disorders involving long-standing (chronic) inflammation of tissues in your digestive tract. Types of IBD include:
Ulcerative colitis. This condition involves inflammation and sores (ulcers) along the lining of your large intestine (colon) and rectum.
Crohn's disease. This type of IBD is characterized by inflammation of the lining of your digestive tract, which often can involve the deeper layers of the digestive tract. Crohn's disease most commonly affects the small intestine. However, it can also affect the large intestine and uncommonly, the upper gastrointestinal tract.
Both ulcerative colitis and Crohn's disease usually are characterized by diarrhea, rectal bleeding, abdominal pain, fatigue and weight loss.
For some people, IBD is only a mild illness. For others, it's a debilitating condition that can lead to life-threatening complications.
Inflammatory Bowel Disease Symptoms
Inflammatory bowel disease symptoms vary, depending on the severity of inflammation and where it occurs. Symptoms may range from mild to severe. You are likely to have periods of active illness followed by periods of remission.
Signs and symptoms that are common to both Crohn's disease and ulcerative colitis include:
Diarrhea
Fatigue
Abdominal pain and cramping
Blood in your stool
Reduced appetite
Unintended weight loss
Do you know the treatment paradigms for different countries? Download our Inflammatory Bowel Disease Market Sample Report
Recent breakthrough in the Inflammatory Bowel Disease
FDA approves first oral treatment for moderately to severely active Crohn’s disease:
FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohn’s disease.
Patients should start with 45 mg of Rinvoq once daily for 12 weeks. Following the 12-week period, the recommended maintenance dosage is 15 mg once a day. A maintenance dosage of 30 mg once daily can be considered for patients with refractory, severe, or extensive Crohn’s disease.
Inflammatory Bowel Disease Epidemiology Segmentation
DelveInsight’s Inflammatory Bowel Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Inflammatory Bowel Disease historical patient pools and forecasted Inflammatory Bowel Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Inflammatory Bowel Disease Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Inflammatory Bowel Disease Prevalence
Age-Specific Inflammatory Bowel Disease Prevalence
Gender-Specific Inflammatory Bowel Disease Prevalence
Diagnosed and Treatable Cases of Inflammatory Bowel Disease
Visit for more @ Inflammatory Bowel Disease Epidemiological Insights
Inflammatory Bowel Disease Treatment Market
The Inflammatory Bowel Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Inflammatory Bowel Disease market trends by analyzing the impact of current Inflammatory Bowel Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
The most common medications used to treat IBD are antibiotics such as metronidazole and ciprofloxacin; ASA anti-inflammatory drugs such as Asacol, Azulfidine, Colazol, Pentasa, Rowasa and Lialda; steroids, such as prednisone, prednisolone or budesonide, immunomodulators such as Imuran(azathioprine), Purinethol, and methotrexate; biologics, such as REMICADE, HUMIRA, CIMZIA, ENTYVIO, STELARA and XELJANZ, nutritional therapy can be used to induce and maintain remission in Crohn’s disease.
There are various drugs currently being studied for the treatment of IBD. The Key players are Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, and others.
According to DelveInsight, the Inflammatory Bowel Disease market in 7MM is expected to witness a major change in the study period 2019-2032.
Inflammatory Bowel Disease Key Companies
Eli Lilly and Company
Gilead
Galapagos
Protagonist Therapeutics
Athos Therapeutics
For more information, visit Inflammatory Bowel Disease Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Inflammatory Bowel Disease Market Report:
10 Years Forecast
7MM Coverage
Descriptive overview of Inflammatory Bowel Disease, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Inflammatory Bowel Disease epidemiology in the 7MM
Inflammatory Bowel Disease marketed and emerging therapies
Inflammatory Bowel Disease companies
Inflammatory Bowel Disease market drivers and barriers
Key Questions Answered in the Inflammatory Bowel Disease Market Report 2032:
What was the Inflammatory Bowel Disease market share distribution in 2019, and how would it appear in 2032?
What is the total Inflammatory Bowel Disease market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Inflammatory Bowel Disease market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Inflammatory Bowel Disease market projected to expand at 7MM?
Table of Contents:
1 Inflammatory Bowel Disease Market Key Comprehensive Insights
2 Inflammatory Bowel Disease Market Report Introduction
3 Competitive Intelligence Analysis for Inflammatory Bowel Disease
4 Inflammatory Bowel Disease Market Analysis Overview at a Glance
5 Executive Summary of Inflammatory Bowel Disease
6 Inflammatory Bowel Disease Epidemiology and Market Methodology
7 Inflammatory Bowel Disease Epidemiology and Patient Population
8 Inflammatory Bowel Disease Patient Journey
9 Inflammatory Bowel Disease Treatment Algorithm, Inflammatory Bowel Disease Current Treatment, and Medical Practices
10 Key Endpoints in Inflammatory Bowel Disease Clinical Trials
11 Inflammatory Bowel Disease Marketed Therapies
12 Inflammatory Bowel Disease Emerging Therapies
13 Inflammatory Bowel Disease: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Inflammatory Bowel Disease
16 Inflammatory Bowel Disease Market Key Opinion Leaders Reviews
18 Inflammatory Bowel Disease Market Drivers
19 Inflammatory Bowel Disease Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Inflammatory Bowel Disease Epidemiology 2032
DelveInsight's "Inflammatory Bowel Disease - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Inflammatory Bowel Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
About DelveInsight:
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Contact Us:
Kritika Rehani
+91-9650213330
www.delveinsight.com
#Inflammatory Bowel Disease market#Inflammatory Bowel Disease market share#Inflammatory Bowel Disease market size#Inflammatory Bowel Disease treatment market#Inflammatory Bowel Disease companies
0 notes
Text
The Human Microbiome Market is projected to grow from USD 910 million in 2024 to an estimated USD 3060.33 million by 2032, with a compound annual growth rate (CAGR) of 16.37% from 2024 to 2032.The human microbiome market is witnessing rapid growth, driven by advancements in healthcare, biotechnology, and a growing understanding of the critical role microorganisms play in human health. The human microbiome, a collection of microorganisms living in and on the human body, has become a focal point for research and innovation, promising to revolutionize personalized medicine, diagnostics, and therapeutics. The human microbiome comprises trillions of microorganisms, including bacteria, fungi, viruses, and archaea, residing in various parts of the body, such as the gut, skin, oral cavity, and respiratory tract. Among these, the gut microbiome has garnered the most attention due to its profound impact on digestion, immunity, and mental health. Disruptions in the microbiome, known as dysbiosis, have been linked to conditions ranging from inflammatory bowel disease (IBD) and obesity to depression and cancer.
Browse the full report at https://www.credenceresearch.com/report/human-microbiome-market
Market Overview
The global human microbiome market is projected to grow significantly, with a compound annual growth rate (CAGR) exceeding 20% over the next decade. The market encompasses several segments, including probiotics, prebiotics, diagnostic tests, therapeutic solutions, and research tools.
Key drivers for this growth include:
Increased Awareness: Public and professional awareness about the importance of a balanced microbiome has surged. Consumers are increasingly seeking probiotic and prebiotic products to support gut health.
Advancements in Genomics: Technological advancements, such as next-generation sequencing (NGS), have enabled deeper insights into the human microbiome, fueling research and development in this field.
Rising Prevalence of Chronic Diseases: With a growing number of people suffering from lifestyle-related and autoimmune diseases, microbiome-based interventions offer potential therapeutic solutions.
Personalized Medicine: The ability to tailor treatments based on an individual's microbiome composition is becoming a cornerstone of precision medicine.
Key Applications in the Market
Probiotics and Prebiotics: Probiotic products, such as yogurts, capsules, and supplements, have become mainstream, supported by evidence linking them to improved gut health and immunity. Prebiotics, the dietary fibers that nourish beneficial gut bacteria, are also gaining popularity.
Therapeutics: Microbiome-based therapies are being developed for a range of diseases. For instance, fecal microbiota transplantation (FMT) has shown effectiveness in treating Clostridioides difficile infections, while emerging therapies target conditions like diabetes, cancer, and neurological disorders.
Diagnostics: Microbiome diagnostics is an emerging segment focusing on identifying microbiome imbalances and disease markers. Companies are developing kits and services that analyze an individual’s microbiome composition for health insights.
Research and Development: Pharmaceutical and biotech companies are investing heavily in microbiome research to identify novel drug targets and validate microbiome-based interventions.
Challenges and Opportunities
Despite its promising outlook, the human microbiome market faces several challenges:
Scientific Complexity: The microbiome is highly complex, and understanding its interactions with the human body is still in its infancy.
Regulatory Hurdles: Regulatory frameworks for microbiome-based products and therapies are evolving, often delaying product approvals.
Market Competition: The market is becoming crowded with startups and established companies, making differentiation a challenge.
However, these challenges also present opportunities:
Collaborations: Partnerships between academia, biotech firms, and pharmaceutical companies can accelerate research and development.
Innovation: Advances in artificial intelligence (AI) and machine learning can facilitate the analysis of microbiome data, paving the way for breakthroughs.
Future Outlook
The human microbiome market holds immense potential to transform healthcare. As research deepens, products and therapies targeting specific microbiome-related conditions will become more sophisticated and accessible. Investments in this field are likely to yield high returns, given the growing demand for personalized and preventive healthcare solutions.
Key Player Analysis:
4D Pharma
AOBiome
Du Pont De Nemours and Co.
Enterome Biosciences SA
Ferring Pharmaceuticals
Metabiomics Corp. (BioSpherex LLC)
Microbiome Therapeutics LLC
Osel, Inc.
Rebiotix, Inc.
Second Genome
Seres Therapeutics
Synthetic Biologics, Inc.
Vedanta Biosciences
Yakult Honsha Co.
Segmentation:
By Product
Probiotics
Prebiotics
Medical Foods
Supplements
Others
By Disease
Infectious
Endocrine
Metabolic
By Application
Therapeutics
Diagnostics
By Type
FMT
Peptide
Live Biotherapeutic Product
Others
By Regional
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Browse the full report at https://www.credenceresearch.com/report/human-microbiome-market
About Us:
Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.
Contact:
Credence Research
Please contact us at +91 6232 49 3207
Email: [email protected]
0 notes
Text
Global Gastrointestinal Drugs Market Size, Share, Growth and Forecast 2031
Global gastrointestinal drugs market is projected to witness a CAGR of 4.23% during the forecast period 2024-2031, growing from USD 45.20 billion in 2023 to USD 62.96 billion in 2031. The market’s growth is boosted by the rising cases of gastrointestinal diseases, novel product launches by the market players, and increasing emphasis on ensuring the availability of gastrointestinal drugs in different regions across the globe.
Technological advancements in drug delivery mechanisms and formulations are enhancing the efficacy of gastrointestinal drugs. The advancements include the development of extended-release and delayed-release formulations that aid in improving the bioavailability and absorption of the drugs, resulting in improved patient outcomes. Such developments are revolutionizing the treatment of ulcerative colitis and Crohn’s disease, among others, providing lucrative growth opportunities for the market.
The rising prevalence of various gastrointestinal disorders, such as celiac disease, is also propelling the growth of the global gastrointestinal drugs market. According to an article published in the StatPearls journal of StatPearls Publishing LLC in August 2023, the prevalence of celiac disease is approximately 0.5% to 1% among the general population. Additionally, the number of cases of Crohn’s disease is also increasing at a rapid rate. According to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, more than half a million people are suffering from Crohn’s disease in the United States. Thus, various pharmaceutical companies are investing in research activities to augment the development of novel therapies to combat the growing threat of Crohn’s disease. In October 2023, Eli Lilly and Company announced that the investigational interleukin-23p19 antagonist, mirikizumab met all major secondary and co-primary endpoints in a phase 3 study, evaluating its efficacy and safety for treating adults with severely to moderately active Crohn’s disease.
Increasing Cases of Gastrointestinal Diseases Boost Market Demand
The rising cases of gastrointestinal distress in various regions across the globe due to changes in lifestyle and eating habits of the population is one of the major factors bolstering the global gastrointestinal drugs market demand. Factors such as increased stress and the rising prevalence of obesity are also propelling the incidences of gastrointestinal diseases. According to the estimates of the World Health Organization (WHO), 1 in 8 people around the world were living with obesity in 2022. This increase is augmenting the incidences of diseases such as peptic ulcers, irritable bowel syndrome, and gastroesophageal reflux disease. Furthermore, the rapid expansion of the aging population is also boosting the demand for gastrointestinal drugs as the older population is more susceptible to gastrointestinal issues. The WHO estimates that approximately 1 in 6 people across the globe will be 60 or older by 2030. Due to the rising occurrences of such issues, pharmaceutical companies are also increasingly focusing on developing innovative therapies that address the underlying cause of the disease rather than alleviating symptoms.
Rising Efforts of Pharma Companies Supports Market Expansion
The rising efforts of the key players in the market to ensure the availability of novel gastrointestinal drugs through investments and partnerships is boosting the global gastrointestinal drugs market size. In June 2024, AbbVie Inc. secured its position in the gastrointestinal drugs market by paying USD 150 million to China-based FutureGen Biopharmaceutical (Beijing) Co., Ltd. in near-term fees for rights to antibody drug targeting TL1A molecule that has been linked with a heightened immune response in cases of inflammatory bowel disease.
Similarly, in June 2024, Akum Drugs and Pharmaceuticals Ltd. unveiled new formulations for gastrointestinal diseases for patients in India. The company’s Rabeprazole + Levosulpiride SR Capsules received approval from the Drug Controller General of India (DCGI). The drugs aim to provide relief to patients suffering from gastrointestinal tract disorders. Rabeprazole sodium, a potent antisecretory compound, has demonstrated efficacy in treating duodenal and gastric ulcers along with gastroesophageal reflux disease by selectively inhibiting the secretion of gastric acid. Such efforts are expected to aid patients suffering from gastrointestinal issues in effectively managing their conditions and provide lucrative growth opportunities to the gastrointestinal drug market.
Retail Pharmacies Hold Significant Market Share
The segment’s expansion can be attributed to the rising requirement for over-the-counter (OTC) gastrointestinal drugs over the past few years due to the rising cases of gastrointestinal distress and consumer preference for immediate relief from common digestive issues, including constipation, acid reflux, diarrhea, and heartburn. As per the American College of Gastroenterology (ACG) estimates, approximately 20% of the population of the United States suffers from gastroesophageal reflux disease. Due to the widespread presence of retail pharmacies and their convenient nature, patients suffering from gastrointestinal issues prefer them for purchasing medication, especially in semi-urban and urban locations.
Meanwhile, online pharmacies are expected to grow rapidly over the next few years due to the growing preference for online shopping, fast delivery, shipping, and the availability of lucrative discounts. Other advantages online pharmacies offer include increased consumer accessibility to a broad range of products. Additionally, the growing popularity of digital consultation and the rising availability of e-prescriptions have also made it easier for patients to avail themselves of the required medications through online pharmacies, bolstering the segment’s growth.
North America Holds Major Market Share
The growth of the North American gastrointestinal drugs market can be attributed to the increasing efforts of the leading market players based in the region to ensure novel product launches, rising cases of gastrointestinal diseases, and the presence of well-established healthcare and pharmaceutical sectors. Various gastrointestinal diseases, including ulcerative colitis, Crohn’s disease, and inflammatory bowel disease, are becoming increasingly prevalent in the United States, bolstering the market’s demand. As per the estimates of the US Centers for Disease Control and Prevention, the prevalence of inflammatory bowel disease is between 2.4 and 3.1 million in the United States, with differing burdens across groups. Additionally, the prominent presence of various research organizations that are increasingly focusing on investigating different gastrointestinal diseases is also expected to influence the market’s expansion positively. Moreover, the increasing availability of novel drugs due to the increasing provision of approvals by the regulatory bodies in the region is also supporting the market’s growth is the region. In 2023, the US Food and Drug Administration (FDA) provided approval to five new gastrointestinal targeted drugs, including colonoscopy prep, inflammatory bowel disease, and gastroesophageal reflux disease. Such approvals are expected to increase the influx of various gastrointestinal drugs in North America.
Download Free Sample Report
Future Market Scenario (2024-2031F)
As per the global gastrointestinal drugs market analysis, the market is expected to witness significant growth in the coming years due to the growing burden of different gastrointestinal diseases and the increasing efforts of the market players towards novel product launches. According to an article published in January 2024 in the Dovepress of the Dove Medical Press Ltd, the prevalence of Crohn’s disease is expected to increase to 1% in 2030 in Western European countries and the United States. This increase will bolster the market’s demand to meet the growing drug requirement for effective management and treatment of the condition. The cases of gastrointestinal distress are also expected to increase in the coming years due to the increasing preference for fast foods and dining out as a fast food-filled diet lacks essential fiber intake, resulting in decreased adoption of water.
Additionally, the market is also expected to witness significant growth over the forecast period due to the rising investments by the leading pharmaceutical companies towards research and development activities and the emphasis on creating targeted therapies that provide minimal side effects along with long-term relief. Furthermore, the growing efforts of various countries to enhance their healthcare sectors and ensure the availability of necessary therapies and treatment solutions are further expected to propel the global gastrointestinal drugs market growth.
Report Scope
“Gastrointestinal Drugs Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global gastrointestinal drugs market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.
Click here for full report- https://www.marketsandata.com/industry-reports/gastrointestinal-drugs-market
Latest reports-
Contact
Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: [email protected] Website: https://www.marketsandata.com
0 notes
Text
United States endoscopy devices market size reached USD 11.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 21 Billion by 2033, exhibiting a growth rate (CAGR) of 6.8% during 2025-2033. The rising incidence of gastrointestinal diseases, such as colorectal cancer, inflammatory bowel disease, and gastroesophageal reflux disease, which has led to an increased demand for endoscopic procedures for both diagnosis and treatment, is driving the market.
#United States Endoscopy Devices Market#United States Endoscopy Devices Market size#United States Endoscopy Devices Market share#United States Endoscopy Devices Market forecast
0 notes
Text
Microbiome Therapeutics Market: Regional Dynamics and Emerging Opportunities
The global Microbiome Therapeutics Market Revenue, valued at USD 132.94 million in 2023, is projected to experience unprecedented growth, reaching USD 1,979.94 million by 2031. This expansion represents a compound annual growth rate (CAGR) of 40.16% over the forecast period from 2024 to 2031. The anticipated surge in market size reflects the increasing interest in microbiome-based therapies as a promising approach to treating a range of chronic and infectious diseases.
Microbiome therapeutics involve the development of therapies that leverage the beneficial properties of the microbiota — the collection of microorganisms residing in the human body — to treat or prevent various health conditions. The rapidly evolving understanding of the microbiome's role in health and disease has driven innovation in this field, leading to the development of novel therapeutic products that can restore the balance of the gut microbiota or target specific pathogens.
Key Market Dynamics and Drivers
The robust growth of the Microbiome Therapeutics Market is primarily driven by the increasing prevalence of chronic diseases, such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic disorders, along with the rising incidence of antibiotic-resistant infections. Microbiome-based therapies offer a new and innovative approach to addressing these conditions by modulating the gut microbiota, thereby improving patient outcomes and reducing dependency on conventional treatments.
Furthermore, the growing body of research supporting the role of the microbiome in immune modulation, metabolic regulation, and disease prevention has spurred investments in the development of microbiome-based drugs. Companies are increasingly focusing on microbiome therapeutics as a viable alternative to traditional pharmaceuticals, driving significant R&D activities and product development efforts in this space.
Get Free Smaple Report@ https://www.snsinsider.com/sample-request/2788
Market Trends
The Microbiome Therapeutics Market is witnessing several key trends that are likely to propel its growth over the forecast period. These include:
Advancements in Microbiome Research: Significant progress in understanding the human microbiome's structure and function has led to the identification of specific microbial strains that can be harnessed for therapeutic purposes. This has opened new avenues for the development of targeted microbiome therapies, particularly for gastrointestinal, metabolic, and immune-related disorders.
Increased Investment in R&D: Pharmaceutical companies and biotech firms are making substantial investments in the development of microbiome-based drugs. Collaborations between academia, research institutions, and industry players are accelerating the discovery of new therapeutic candidates and the commercialization of microbiome products.
Rising Consumer Awareness: As consumers become more aware of the benefits of maintaining a healthy gut microbiome, there is an increasing demand for products that support microbiome health, including probiotics, prebiotics, and synbiotics. This trend is further driving interest in microbiome therapeutics.
Regulatory Support: Regulatory bodies in various countries are recognizing the potential of microbiome-based treatments and are providing frameworks for the approval and commercialization of these products. This support is expected to facilitate the entry of new players into the market and encourage the development of innovative therapies.
Regional Insights
North America held the largest share of the Microbiome Therapeutics Market in 2023, owing to its well-established healthcare infrastructure, high investment in R&D, and strong presence of key industry players. The region's focus on developing advanced therapies for chronic diseases and antibiotic-resistant infections has contributed to its leadership position in the market.
The Asia-Pacific region is expected to register the highest growth rate during the forecast period, driven by rising healthcare awareness, increasing prevalence of chronic conditions, and expanding investment in the life sciences sector. Countries such as China, Japan, and South Korea are at the forefront of microbiome research and are poised to play a crucial role in the market's growth.
Leading Companies in the Market
The Microbiome Therapeutics Market features a diverse range of players, from established pharmaceutical companies to emerging biotech firms. Some of the leading companies in this space include Seres Therapeutics, Vedanta Biosciences, Synlogic, Finch Therapeutics, and Evelo Biosciences. These companies are focusing on strategic collaborations, mergers, and acquisitions, as well as product innovation to enhance their market presence and cater to the growing demand for microbiome-based therapies.
Conclusion
The global Microbiome Therapeutics Market is set to witness exponential growth over the next decade, driven by increasing research, growing investment, and rising awareness of the microbiome's role in human health. As the demand for effective, targeted, and personalized treatments continues to rise, microbiome therapeutics are expected to emerge as a pivotal solution in the global healthcare landscape, offering new hope for patients with chronic and complex diseases.
0 notes
Text
On-body Injectors Market Size To Reach $12.7 Billion By 2030
The global on-body injectors market size is expected to reach USD 12.7 billion by 2030, registering a CAGR of 14.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The on-body injectors increase patient adherence to medication by offering easy-to-use, less pain and enabling extended drug administration without frequent hospital visits. These advantages of on-body injectors are significantly increasing their popularity. Moreover, regions such as Asia Pacific, with developing healthcare infrastructure and rising adoption of advanced medical devices, offer huge opportunities for market growth over the forecast period.
The increasing concerns over needle stick injuries and the need to increase the safety for both patients and healthcare professionals by eliminating risks associated with needle insertion, drug preparation, and covering & disposing of needles, coupled with the increasing prevalence of chronic diseases such as cancer are some of the factors expected to drive the market growth over the forecast period.
According to the WHO agency International Agency for Research on Cancer (IARC), around 20 million people were diagnosed with cancer, and around 9.7 million mortalities occurred due to cancer in 2022. Several cancers and other chronic disease treatments require frequent injections of medications over extended periods. On-body injectors offer a convenient and potentially less disruptive alternative for patients to receive these medications compared to traditional hospital visits or self-administered injections, which can significantly increase their demand over the forecast period.
Request a free sample copy or view report summary: On-body Injectors Market Report
On-body Injectors Market Report Highlights
Based on the technology, the spring-based segment accounted for the largest revenue share of 40.89% in 2023 owing to their consistent pressure and speed, which ensures precise dosing
Based on technology, the rotary pump segment is expected to grow at the fastest CAGR of 15.1% during the forecast period owing to the high control offered by them in dispensing medications, minimizing the risk of dosing errors and maximizing therapeutic efficacy
Based on the application, the diabetes segment accounted for the largest revenue share in 2023 due to the high prevalence of type 2 diabetes, which requires frequent administration
Based on the application, the autoimmune diseases segment is expected to grow at the fastest CAGR owing to the rising prevalence of chronic autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and Inflammatory Bowel Diseases (IBD)
Based on the end use, the homecare segment accounted for the largest revenue share in 2023 owing to the growing preference for self-administration of medications for managing chronic conditions such as diabetes, autoimmune disorders, and cancer in homecare settings
In 2023, North America dominated with a share of 33.17%, driven by the presence of key market players, an increasing shift toward home care, and better access to advanced on-body injectors
On-body Injectors Market Segmentation
Grand View Research has segmented the global on-body injectors market based on technology, application, end-use, and region:
On-body Injectors Technology Outlook (Revenue, USD Million, 2018 - 2030)
Spring-based
Motor-driven
Rotary Pump
Expanding Battery
Other
On-body Injectors Application Outlook (Revenue, USD Million, 2018 - 2030)
Oncology
Diabetes
Cardiovascular Disease
Autoimmune Disease
Others
On-body Injectors End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals & Clinics
Home Care Settings
Others
On-body Injectors Region Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the On-body Injectors Market
West Pharmaceutical Services, Inc.
BD
Stevanato Group
Enable Injections
Nemera
Debiotech SA
AbbVie, Inc.
Coherus BioSciences, Inc.
Gerresheimer AG
E3D Elcam Drug Delivery Devices
0 notes
Text
Necrotising Enterocolitis Market Will Grow At Highest Pace Owing To Rising Prevalence Of Preterm Birth Complications
Necrotising enterocolitis (NEC) is a devastating gastrointestinal disease that primarily affects premature infants. It is characterized by inflammation and necrosis of the intestine. The risk factors associated with NEC include prematurity, formula feeding, and bacterial colonization of the intestine. Infants with very low birth weights have the highest risk. NEC treatment involves management of sepsis, support of vital organ function, bowel rest with no oral feeding, and surgery if necessary.
The Necrotising Enterocolitis Market is estimated to be valued at US$ 7.10 Bn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Necrotising Enterocolitis market are AbbVie, AstraZeneca, Baxter International, Bristol-Myers Squibb, Fresenius Kabi. Rising prevalence of preterm birth complications globally is expected to drive the growth of the market during the forecast period. According to the World Health Organization, preterm birth complications are the leading cause of death among children under 5 years of age, responsible for approximately 1 million deaths in 2015. Technological advancements in parenteral nutrition and minimal invasive surgery have provided improved treatment outcomes for NEC.
Market Trends
Increasing research on nutraceuticals and probiotics for NEC prevention: Several clinical studies are evaluating the role of pre and probiotics such as Lactobacillus and Bifidobacterium in reducing the risk of NEC in preterm infants. This presents an opportunity for novel prevention strategies.
Rising adoption of minimal invasive surgery: Advancements in minimal invasive surgical techniques such as laparoscopy has resulted in reduced recovery time and complications for NEC patients undergoing surgery. This trend is expected to drive the future demand.
Market Opportunities
Development of novel therapeutics targeting inflammatory pathways: Researchers are investigating potential drug targets such as Toll-like receptor 4 (TLR4) and nuclear factor kappa B (NF-κB) signaling pathways to develop novel anti-inflammatory therapies for NEC treatment.
Increasing healthcare expenditure on pediatric care in emerging nations: Emerging countries in Asia Pacific and Latin America are witnessing increased healthcare spending focused on neonatal and pediatric care. This will propel the growth of therapeutics and medical devices market for pediatric gastrointestinal conditions.
Impact Of COVID-19 On Necrotising Enterocolitis Market Growth
The COVID-19 pandemic has adversely impacted the growth of the necrotising enterocolitis market globally. During the peak of pandemic in 2020-2021, the concentration of healthcare resources towards treatment of COVID-19 patients has negatively affected the diagnosis and treatment of other health conditions including necrotising enterocolitis. This led to reduction in number of surgeries and procedures carried out for necrotising enterocolitis management. Moreover, restrictions on non-essential healthcare services along with fear of virus spread stopped patients from visiting hospitals even for emergency cases. This impacted the market growth negatively during the period.
However, with gradual lift of restrictions in 2022 and availability of COVID-19 vaccines, the market is recovering slowly. The healthcare facilities are focusing on clearing backlog of non-COVID cases and regaining lost momentum in treatment of other diseases. The manufacturers are expanding supply chain capabilities and ramping up production to meet the increasing demand. Various initiatives are being taken by governments and healthcare organizations to raise awareness about timely management of necrotising enterocolitis. This will potentially boost the market in the coming years.
The United States holds the major share of necrotising enterocolitis market in terms of value, owing to large patient population, high treatment cost and adequate reimbursement framework. The region accounted for over 35% revenue share of global market in 2024.
Asia Pacific region is poised to witness fastest growth during the forecast period. Factors such as increasing healthcare expenditure, rising medical tourism, growing birth rate and expanding private hospital infrastructure will aid the market growth in Asia Pacific. China, India and Japan are emerging as profitable markets for necrotising enterocolitis treatment.
Get more insights on this topic: https://www.trendingwebwire.com/necrotising-enterocolitis-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-parenteral-nutrition-solutions-and-devices/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
What Are The Key Data Covered In This Necrotising Enterocolitis Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Necrotising Enterocolitis Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Necrotising Enterocolitis Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Necrotising Enterocolitis Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Necrotising Enterocolitis Market vendors
FAQ’s
Q.1 What are the main factors influencing the Necrotising Enterocolitis Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Necrotising Enterocolitis Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Necrotising Enterocolitis Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it
#Necrotising Enterocolitis Market Trend#Necrotising Enterocolitis Market Size#Necrotising Enterocolitis Market Information#Necrotising Enterocolitis Market Analysis#Necrotising Enterocolitis Market Demand
0 notes
Text
Endoscopic Clips Market Size & Share to Surpass USD 632.5 million by 2031
The endoscopic clips industry was worth US$ 383.7 million in 2022. By the end of 2031, it is expected to reach US$ 632.5 million, growing at a CAGR of 5.8% during the forecast period. The use of robotic-assisted surgery in combination with endoscopic procedures is on the rise.
With endoscopic clips designed to integrate with robotic systems in the future seamlessly, minimally invasive surgeries may be enhanced in precision and control. Medical device manufacturers are researching biodegradable materials. There is a possibility of biodegradable endoscopic clips in the future, which would eliminate the need to remove the clips in some cases.
This would likely result in fewer long-term complications. Over the past few years, global healthcare expenditures have increased, enabling the development of advanced medical technologies, including endoscopic clips. Innovative endoscopic clip products can be developed, commercialized, and researched by providing financial support.
For More Details, Request for a Sample of this Research Report: https://www.transparencymarketresearch.com/endoscopic-clips-market.html
Key Findings of the Market Report
By 2022, North America dominated the endoscopic clips market.
Based on application, the hemostasis segment will drive market growth for endoscopic clips.
In terms of end-users, the hospital segment is predicted to drive demand for endoscopic clips.
Manufacturers of endoscopic clips are developing advanced and specialized clips for niche medical applications.
Global Endoscopic Clips Market: Key Players
Several major players hold major market share in the global endoscopic clips industry. Endoscopic clip market trends are driving manufacturers to develop sophisticated and specialized endoscopic clips for niche medical uses. Their production strategy also emphasizes reducing costs and increasing the quality of their endoscopic clips.
Cook Endoscopy
Olympus America
Boston Scientific Corporation
CONMED Corporation
Medtronic
Ovesco Endoscopy AG
Global Endoscopic Clips Market: Growth Drivers
Laparoscopic and endoscopic procedures use endoscopic clips to minimize damage. Less invasive surgeries are becoming more popular, leading to an increase in endoscopic clip demand. The number of gastrointestinal disorders is rising, including polyps, tumors, and gastrointestinal bleeding. The demand for these medical devices is boosted by using endoscopic clips to treat and manage these conditions.
Enhanced imaging capabilities and flexible endoscopes make endoscopic procedures more effective as technology advances. The use of endoscopic clips facilitates the increased adoption of these technologies. Globally, diseases and conditions requiring medical intervention are rising as the population ages. GI issues are more common among older individuals, increasing their need for endoscopic procedures and clips.
Endoscopic clips have been used in various medical fields, including urology, gastroenterology, and gynecology. Endoscopic clips are widely accepted and adopted because of their versatility in different medical field. Patient preferences are shifting towards less invasive treatment options due to decreased pain, faster recovery, and fewer hospital stays. To minimize trauma to the body, endoscopic clips are being used in procedures that focus on patient-centric care.
Increased awareness among healthcare professionals and continuing education initiatives enhance the proper use of endoscopic clips in clinical settings. The endoscopic clip market's growth depends on regulatory approvals for new products and technologies. Research and development are encouraged by positive regulatory environments and approvals.
Global Endoscopic Clips Market: Regional Landscape
Endoscopic clips are expected to be most popular in North America. The United States and Canada will likely drive demand for endoscopic clips. Inflammatory bowel diseases and colorectal cancer are relatively common in North America. These conditions are commonly diagnosed and treated using endoscopic clips, which contributes to their demand.
North America is a leader in healthcare technology. As endoscopic technologies advance and clip designs and functionality improve, the demand for endoscopic clips increases. Medical specialists in different specialties perform diagnostic and therapeutic endoscopic procedures in the region. It is expected that the demand for these clips will increase as endoscopic clips become increasingly popular during these procedures for controlling bleeding, securing tissue, and closing incisions.
Investing in advanced medical technologies is possible in North America due to its relatively high healthcare expenditures. Innovations in endoscopic clips are made possible through this financial support. Due to the well-established regulatory environment in North America, medical devices are subject to strict safety and efficacy standards. Because of this regulatory support, healthcare professionals feel more confident about using the product and the market grows.
Global Endoscopic Clips Market: Segmentation
By Application
Endoscopic Marking
Hemostasis
Mucosal/Submucosal Defects
Bleeding Ulcers
Bleeding Arteries
Polypectomy Sites
Others
By End User
Hospitals
Ambulatory Surgical Centers
Clinics
Others
By Region
North America
Latin America
Asia Pacific
Europe
Middle East & Africa
Buy this Premium Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=25967<ype=S
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
0 notes
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2032
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market Trends share, size, growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 162.3 Million in 2023 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 319.1 Mn in 2032.
What are Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
#Primary Sclerosing Cholangitis Market share#Primary Sclerosing Cholangitis Market size#Primary Sclerosing Cholangitis Market trends
0 notes
Text
Psoriatic Arthritis Clinical Trials, Emerging Therapies, Key Companies | A Drug Pipeline Analysis Report 2024 | DelveInsight
DelveInsight’s 'Psoriatic Arthritis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Psoriatic Arthritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Psoriatic Arthritis pipeline domain.
Key Takeaways from the Psoriatic Arthritis Pipeline Report
Over 50+ Psoriatic Arthritis pipeline therapies are in various stages of development, and their anticipated acceptance in the Psoriatic Arthritis market would significantly increase market revenue.
Leading Psoriatic Arthritis companies developing novel drug candidates to improve the Psoriatic Arthritis treatment landscape include AbbVie, and others.
Promising Psoriatic Arthritis pipeline therapies in various stages of development include ABT-494, Risankizumab, and others.
Psoriatic Arthritis Overview
Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling.
Psoriatic arthritis is considered as seronegative spondyloarthropathies. The fact that it is Seronegative is that the blood tests negative for some factors that is present in rheumatoid arthritis.
Spondyloarthropathy describes a group of conditions that all share common characteristics. First, there is a presence of arthritis that affects the spine. Second, inflammation occurs in ligaments, tendons and sometimes in other organs such as the eye.
Request for a sample report to know more about Psoriatic arthritis treatment algorithm and diagnosis.
Psoriatic Arthritis Pipeline Analysis: Drug Profile
Risankizumab: Abbvie
Risankizumab is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases, including psoriasis.
Discover more about the emerging Psoriatic Arthritis drugs @ Psoriatic Arthritis Treatment Drugs
Psoriatic Arthritis Key Companies
AbbVie
Psoriatic Arthritis Pipeline Therapies
ABT-494
Risankizumab
Psoriatic Arthritis Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Psoriatic Arthritis Pipeline Report
Coverage: Global
Key Psoriatic Arthritis Companies: AbbVie, and others
Key Psoriatic Arthritis Pipeline Therapies: ABT-494, Risankizumab, and others
Find out more about the Psoriatic Arthritis treatment options in development @ Psoriatic Arthritis Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Kritika Rehani
+91-9650213330
0 notes
Text
The iron deficiency injectable market is experiencing significant growth, underscored by projected market values of USD 12,045.95 million in 2024, escalating to an estimated USD 23,874.19 million by 2032. This growth trajectory has a compound annual growth rate (CAGR) of 8.93%. Iron deficiency is a widespread health issue affecting millions globally. It leads to anemia, characterized by a lack of healthy red blood cells, which impairs the transport of oxygen throughout the body. Symptoms can include fatigue, weakness, and shortness of breath. For many, dietary changes and oral supplements are effective treatments. However, for those who cannot absorb iron orally or require rapid replenishment, injectable iron therapies have become an essential solution. The market for iron deficiency injectables is growing significantly, driven by increasing awareness, rising prevalence of iron deficiency anemia (IDA), and advancements in medical treatments.
Browse the full report at https://www.credenceresearch.com/report/iron-deficiency-injectable-market
Market Dynamics
Rising Prevalence of Iron Deficiency Anemia
The prevalence of IDA is a primary driver of the iron deficiency injectable market. According to the World Health Organization (WHO), over 1.6 billion people suffer from anemia globally, with iron deficiency being the most common cause. Populations at higher risk include pregnant women, young children, and individuals with chronic diseases such as chronic kidney disease (CKD) and inflammatory bowel disease (IBD). As awareness of iron deficiency and its consequences increases, the demand for effective and quick treatment options is also rising.
Limitations of Oral Iron Supplements
While oral iron supplements are the first line of treatment for iron deficiency, they come with limitations. Gastrointestinal side effects, such as constipation, nausea, and abdominal pain, can reduce patient compliance. Additionally, certain conditions, like malabsorption syndromes and severe IDA, may render oral supplements ineffective. Injectable iron therapies bypass the gastrointestinal tract, providing a direct and rapid replenishment of iron stores, making them a preferred option for many healthcare providers.
Market Segmentation
By Product Type
The iron deficiency injectable market can be segmented based on the type of product. The main types include:
- Iron Dextran: One of the oldest and most commonly used injectable iron formulations. It is effective but has a risk of allergic reactions. - Ferric Carboxymaltose:*Known for its high dose and rapid administration capability with fewer allergic reactions. - Iron Sucrose: Widely used, especially in patients with CKD, due to its favorable safety profile. - Ferumoxytol: Often used for patients with CKD due to its rapid administration and minimal allergic reactions.
By End-User
The market is also segmented based on end-users:
- Hospitals: Major consumers due to the high volume of patients requiring injectable iron treatments. - Clinics: Smaller healthcare settings also contribute significantly to the market. - Home Healthcare: Increasing adoption of home healthcare services has created a niche market for at-home iron deficiency treatments.
Regional Analysis
North America
North America holds a significant share of the iron deficiency injectable market. High prevalence of IDA, advanced healthcare infrastructure, and increased healthcare expenditure are the key factors driving the market in this region. The United States, in particular, sees substantial demand due to a high number of CKD and IBD patients.
Europe
Europe is another major market, with countries like Germany, France, and the UK leading the demand. The presence of established pharmaceutical companies and high awareness levels contribute to market growth.
Asia-Pacific
The Asia-Pacific region is expected to witness the fastest growth. Rapid urbanization, improving healthcare infrastructure, and increasing awareness about IDA are propelling the market forward. Countries like India and China, with large populations, represent significant market potential.
Latin America and Middle East & Africa
These regions are gradually emerging as important markets. Improving healthcare facilities and rising awareness about iron deficiency are driving growth, albeit at a slower pace compared to other regions.
Future Outlook
The iron deficiency injectable market is poised for continued growth. Ongoing research and development efforts aimed at improving the safety and efficacy of injectable iron products, coupled with rising awareness about iron deficiency anemia, are expected to drive market expansion. Additionally, the increasing prevalence of chronic diseases and the limitations of oral iron supplements will further boost the demand for injectable therapies.
Top Key Players
DAIICHI SANKYO COMPANY, LIMITED
Fresenius Kabi AG
Vifor Pharma Management Ltd.
PHARMACOSMOS A/S
Covis Pharma GmbH
Novartis AG
Aetna Inc
Pfizer Inc
Shield Therapeutics plc
American Regent, Inc.
Rockwell Medical, Inc.
Apotex Inc
Bayer AG
Akebia Therapeutics, Inc.
GSK plc
AbbVie Inc
Systacare Remedies
BSA Pharma, Inc.
Segmentations:
By Product Type
Iron Dextran
Iron Sucrose
Ferric Carboxymaltose
Others
By Application
Cancer
Chronic kidney disease
Inflammatory Bowel Disease
Others
By End User
Homecare
Specialty Clinics
Hospitals
Others
By Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Browse the full report at https://www.credenceresearch.com/report/iron-deficiency-injectable-market
About Us:
Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.
Contact:
Credence Research
Please contact us at +91 6232 49 3207
Email: [email protected]
Website: www.credenceresearch.com
0 notes
Text
Global Inflammatory Bowel Disease Market Size, Share, Growth and Forecast 2031
Global inflammatory bowel disease market is projected to witness a CAGR of 5.15% during the forecast period 2024-2031, growing from USD 22.07 billion in 2023 to USD 32.98 billion in 2031. The market demand for Inflammatory Bowel Disease is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.
Inflammatory Bowel Disease is a chronic inflammatory condition of the gastrointestinal tract. It includes two types: Ulcerative colitis and Crohn’s disease. Ulcerative colitis causes swelling and sores in the colon and rectum. Moreover, Crohn’s disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and anus. Common inflammatory bowel disease symptoms include abdominal pain, diarrhea (sometimes with blood), weight loss, rectal bleeding, fever, anemia, anxiety and depression. The diagnostic process for IBD involves multiple approaches. Clinicians typically start with a detailed medical history and physical examination. Some of the associated procedures include blood tests to evaluate anemia or inflammation, stool tests to exclude infection, and imaging studies such as CT scans or MRIs. The diagnosis is typically established through endoscopic procedures, namely colonoscopy, which permits direct visualization of the mucosal surfaces of the intestinal tract and tissue samples (biopsies) taken for further examination. For instance, as per a systematic review article published on 17 June 2024, reported that the incidence rate of Ulcerative Colitis and Crohn’s Disease in the European region is approximately 24.3 and 12.7 per 100,000, respectively. The annual incidence rates for Ulcerative Colitis and Crohn’s Disease in North America were reported at 19.2 and 20.2 per 100,000 individuals annually. The incidence of IBD in Asia ranges from 0.5 to 3.4 per 100,000 individuals, signifying the dynamic changing face of this emerging disease condition in the region. Incidence has risen over the past 10–15 years in Korea, Japan, China, Hong Kong, and India. The increase was more impressive in countries adopting a Western industrialized lifestyle.
Increase in the Prevalence of Inflammatory Bowel Disease
The increase in the prevalence of Ulcerative colitis and Crohn’s disease is anticipated to fuel the growth of the inflammatory bowel disease market. Increasing inflammatory bowel disease is now emerging as a public health problem that is increasingly taking over industrialized nations. Several causes exist for the increase in this disease, with one significant cause being lifestyle changes: diets high on processed foods and low in fiber negatively impact health and gut health. In addition, the hygiene hypothesis provides an insight revealing that lower exposure to infections in the childhood period shows increased risk factors for autoimmune diseases, such as IBD. An urgent need to do further research into causes and treatments of IBD is a critical reason for the greater number of diagnosed cases. Public education campaigns are also needed towards communities about IBD for early detection and proper management of the disease. Considering that more people are living with the burden of IBD, managing this chronic illness needs a collective effort by providers, researchers, and policymakers to give better care and support to affected patients. For instance, in April 2024, Takeda Pharmaceutical Company Limited received approval from the U.S. Food and Drug Administration for ENTYVIO (vedolizumab) subcutaneous (SC) administration for the treatment in adults with moderately to severely active Crohn’s disease (CD).
Advancements in the Treatment Options for Inflammatory Bowel Disease
Advancements in the treatment of inflammatory bowel disease include a wide approach to managing this chronic condition, such that patients are offered more effective and targeted therapies. Indeed, biologics, which target inflammatory pathways by specifically targeting cells, pathways, or molecules that contribute to inflammation, have revolutionized the management of this disease, from addressing underlying pathogenic mechanisms to the historical approach of symptom relief. Moreover, biologics like anti-TNF agents and integrin inhibitors have also proven useful in many patients’ induction and maintenance of remission. New small molecules and JAK inhibitors are also emerging as additional alternatives in some cases. Personalized medicine has also advanced the ability of doctors to treat individual patients according to their individual genetic makeup and disease characteristics, thus offering a better chance for positive outcomes. Continued research and clinical trials are discovering additional new therapeutic targets, as well as new combination therapies, promising higher efficacy and safety. For instance, on 19 February 2024, Pfizer Inc. received approval from the European Commission (EC) granting marketing authorization for VELSIPITY (etrasimod) to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or was intolerant to either conventional therapy or a biological agent. VELSIPITY is the first and only advanced oral ulcerative colitis treatment approved for use in patients 16 years of age.
Crohn’s Disease Segment to Dominate the Inflammatory Bowel Disease Market
The Crohn’s disease segment dominates the inflammatory bowel disease market due to the high prevalence and the specific need for treatment. Often, Crohn’s disease affects any part of the gastrointestinal tract and generally causes more severe and varied symptoms than ulcerative colitis does, so its requirements are more complex, thus dictating a wide range of treatment options, including biologics, immunosuppressants, and emerging therapies tailored according to the needs of the individual patient. Other drivers for the growth of this segment include improved diagnosis techniques and increased awareness. Research and clinical studies in Crohn’s disease continue to drive ongoing innovations and therapies that improve patient outcomes significantly, thus driving growth in the market. Also, with healthcare providers seeking more practical treatments for this chronic condition, the Crohn’s disease market is poised to capture a greater share of the inflammatory bowel disease market. For instance, on 18 May 2023, AbbVie Inc. received approval from the U.S. Food and Drug Administration for RINVOQ (upadacitinib) to treat adults with moderate to severely active Crohn’s disease.
North America Dominates Inflammatory Bowel Disease Market
North America dominates the Inflammatory Bowel Disease (IBD) market, primarily driven by a combination of high prevalence rates, advanced healthcare infrastructure, and significant investment in research and development. The incidences of ulcerative colitis in North America range from 2.2 to 19.2 cases per 100,000 person-years, and Crohn’s disease incidences range from 3.1 to 20.2 cases per 200,000 person-years. In the United States the prevalence of adult ulcerative colitis was 238 per 100,000 population and 201 per 100,000 population with data from a large study based on insurance claims. Inflammatory bowel disease is more prevalent in North America and Europe than in Asia or Africa. The region has a well-established healthcare system that makes it easier to administer new, advanced therapies such as biologics and emerging medications specifically designed to meet the needs of each patient. Well-organized awareness programs and support groups help facilitate earlier diagnosis and optimal management of the disease. For instance, on August 12, 2024, Celltrion USA, Inc. (Celltrion USA) received approval from the Food and Drug Administration for biosimilar adalimumab-aaty. Adalimumab-aaty is approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease and Ulcerative colitis. The treatment for self-funded employer plans was available in the U.S. from Costco Specialty Pharmacy on October 1, 2023.
Download Free Sample Report
Future Market Scenario (2024-2031F)
The future market scenario seems promising for the inflammatory bowel disease market, influenced by factors that increase demand and investment in this market. The inflammatory bowel disease market is full of promise with the continuous advancement in research, technology, and options available for treatment. Moving into the future, with an increased understanding of the mechanisms driving IBD, more targeted therapies are emerging, such as biologics and small molecules targeting some of the pathways responsible for inflammation. In addition, the increasing incidence of IBD in emerging markets and globally will increase the patient population, which requires effective management systems. Improved diagnosis and early detection methods will ensure timely interventions, which will be beneficial to the patients and improve their quality of life. Other factors that will drive innovation in the field are stronger investment in research and more collaboration between pharmaceutical companies and academic institutions. For instance, on 4 October 2023, Sanofi and Teva Pharmaceuticals announced a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, the two types of inflammatory bowel disease.
Report Scope
“Inflammatory Bowel Disease Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global inflammatory bowel disease market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.
Click here for full report- https://www.marketsandata.com/industry-reports/inflammatory-bowel-disease-market
Latest reports-
Contact
Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: [email protected] Website: https://www.marketsandata.com
0 notes
Text
United States endoscopy devices market size is projected to exhibit a growth rate (CAGR) of 6.79% during 2024-2032. The rising incidence of gastrointestinal diseases, such as colorectal cancer, inflammatory bowel disease, and gastroesophageal reflux disease, which has led to an increased demand for endoscopic procedures for both diagnosis and treatment, is driving the market.
#United States Endoscopy Devices Market#United States Endoscopy Devices Market size#United States Endoscopy Devices Market share#United States Endoscopy Devices Market forecast#United States Endoscopy Devices Market 2024#United States Endoscopy Devices Market trends
0 notes
Text
Microbiome Therapeutics Market Size: Regulatory Framework
The Microbiome Therapeutics Market size was valued at USD 132.94 million in 2023 and is expected to reach at USD 1979.94 million by 2031, and grow at a CAGR of 40.16% over the forecast period of 2024-2031.The microbiome therapeutics market is experiencing rapid growth, driven by groundbreaking research into the role of the human microbiome in health and disease. This burgeoning field focuses on developing treatments that target the microbiome, leveraging beneficial microbes or modulating microbial communities to combat various conditions, including gastrointestinal disorders, metabolic diseases, and even mental health issues. Innovations in microbiome therapeutics are not only paving the way for personalized medicine but are also attracting significant investment from pharmaceutical giants and biotech startups. As scientific understanding deepens, the market is poised to revolutionize healthcare, offering novel solutions that move beyond traditional pharmaceuticals by harnessing the power of the body's own microbial ecosystem.
Get Sample Copy Of This Report @ https://www.snsinsider.com/sample-request/2788
Market Scope & Overview
The authentic market data supports critical decision-making for growth and profitability as well as performance monitoring. By concentrating on markets, materials, capacities, technologies, and the shifting make-up of the global Microbiome Therapeutics Market market, the market research report provides information on trends and developments. New vendors entering the market are having a hard time competing with the overseas suppliers due to their higher quality, dependability, and technological advancements.
In this market research report, the most recent research provides a thorough overview and in-depth market analysis. The competition in the Microbiome Therapeutics Market grows along with sector expansion and technological innovation. For a wide range of end users, a huge number of regional and local producers also offer specialized application goods.
Market Segmentation Analysis
By Type
FMT
Microbiome Drugs
By Application
difficile
Crohn’s disease
Inflammatory Bowel Disease
Diabetes
Others
COVID-19 Pandemic Impact Analysis
In order to give clients accurate information to address market challenges during and after the COVID-19 pandemic, several industry experts and delegates are interviewed for a report on the Microbiome Therapeutics Market during the primary and secondary research phases. The market dynamics during the forecast period are examined in-depth, along with observations of significant changes over time, in this market research analysis.
Regional Outlook
In addition to observations, the Microbiome Therapeutics Market research report also includes a quick scan of potential competitors and a competition analysis. The study report includes analyses of the regional business environment, market dynamics and drivers, opportunities and challenges, risk and entry barriers, and production and distribution networks in addition to Porter's five forces analysis.
Competitive Analysis
A quantitative evaluation of the market's condition by registration, organizational setup, and geographic regions makes up the primary research report. The focus of Microbiome Therapeutics Market research should be on current developments, future prospects, and market trends globally. The study looks into the potential for local growth and offers a thorough analysis of a number of industries.
Key Questions Answered in the Microbiome Therapeutics Market Report
Which regional market will offer the most lucrative opportunities in the coming years?
What marketing tactics can businesses in developed regions use to gain a competitive edge?
What marketing strategy affects a company's market share the most?
Conclusion
The Microbiome Therapeutics Market research report looks at the economic situation of the target industry as well as showing that there is a robust market and inclusive demand.
About Us
SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.
When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.
Related Reports
Flash Chromatography Market Size
Cystic Fibrosis Market Size
Cancer Biopsy Market Size
Glaucoma Therapeutics Market Size
Genomics Services Market Size
0 notes
Text
Inflammatory Bowel Disease Drugs Market 2024 | Outlook, Growth By Top Companies, Regions, Types, Applications, Drivers, Trends & Forecasts by 2031
The global Inflammatory Bowel Disease drugs market has witnessed significant growth in recent years, with a trajectory set to continue upward. Valued at USD 20.55 billion in 2022, it is projected to reach USD 26.85 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 3.4% during the forecast period from 2023 to 2030. This growth is fueled by several key factors, including emerging trends, evolving treatment landscapes, and expanding opportunities in the healthcare sector.
Emerging Trends and Opportunities:
Biologics Dominance: Biologic therapies have revolutionized the treatment of IBD, offering targeted approaches with fewer side effects compared to traditional medications. The increasing adoption of biologics, alongside the development of biosimilars, is a notable trend driving market growth.
Personalized Medicine: Advancements in genetics and molecular diagnostics have paved the way for personalized treatment approaches in IBD. Tailoring therapies based on individual patient characteristics, such as genetic markers and disease severity, is gaining traction, leading to more effective and targeted interventions.
Novel Drug Development: Pharmaceutical companies are investing heavily in research and development to bring forth innovative therapies for IBD. From small molecule inhibitors to novel biologics targeting specific pathways implicated in the disease, the pipeline for new treatments is robust, offering promising opportunities for market expansion.
Telemedicine and Digital Health: The COVID-19 pandemic accelerated the adoption of telemedicine and digital health solutions in healthcare delivery. For patients with IBD, remote monitoring, teleconsultations, and mobile health apps offer convenience and improved access to care, presenting a growing market segment for digital health solutions in IBD management.
Download Free Sample Report: https://www.snsinsider.com/sample-request/2988
Key Drivers Propelling Growth:
Rising Disease Prevalence: The prevalence of IBD, including Crohn's disease and ulcerative colitis, is increasing globally, particularly in developed regions. This demographic trend, coupled with better disease awareness and diagnosis, is driving the demand for IBD drugs.
Healthcare Infrastructure Development: Emerging economies are witnessing rapid development in healthcare infrastructure, including increased healthcare spending, improved access to advanced therapies, and enhanced medical facilities. This expansion of healthcare infrastructure creates a conducive environment for market growth.
Regulatory Support and Market Access: Regulatory agencies are streamlining approval processes for IBD drugs, expediting market entry for new treatments. Moreover, initiatives aimed at ensuring affordable access to essential medicines are facilitating market penetration and adoption, especially in emerging markets.
Challenges and Considerations:
High Treatment Costs: The cost of biologic therapies for IBD remains substantial, posing challenges for affordability and access, particularly in resource-constrained settings. Addressing pricing pressures and ensuring equitable access to innovative therapies are imperative for sustainable market growth.
Safety and Efficacy Concerns: While biologic therapies offer significant clinical benefits, concerns regarding long-term safety and efficacy persist. Continued surveillance and post-market monitoring are essential to mitigate risks and ensure the optimal use of IBD drugs.
Patent Expirations and Biosimilar Competition: The impending patent expirations of key biologic drugs in the IBD market will pave the way for biosimilar competition, potentially leading to pricing pressures and market fragmentation. Pharmaceutical companies must navigate this landscape strategically to maintain market share and competitiveness.
Key Takeaways from the Market:
Biologic therapies are driving significant growth in the IBD drugs market, supported by advancements in personalized medicine and novel drug development.
Digital health solutions and telemedicine are reshaping IBD management, offering opportunities for improved patient care and engagement.
Addressing affordability and access challenges, along with ensuring the safety and efficacy of IBD drugs, are critical considerations for sustainable market growth.
Regulatory support, healthcare infrastructure development, and rising disease prevalence are key drivers propelling market expansion, particularly in emerging economies.
In conclusion, the Inflammatory Bowel Disease drugs market is poised for continued growth, driven by emerging trends, evolving treatment paradigms, and expanding opportunities in the healthcare sector. However, addressing challenges related to affordability, safety, and access will be crucial in realizing the full potential of this dynamic market.
0 notes